Skip to main content
Fig. 4 | BMC Cancer

Fig. 4

From: Probabilistic modeling of personalized drug combinations from integrated chemical screen and molecular data in sarcoma

Fig. 4

Probabilistic Target Inhibition Maps (PTIMs) of Drug Screen V3 and Roche screen results for spatially-distinct epithelioid sarcoma tumor regions. Values in the center of PTIM blocks represent expected scaled sensitivity following inhibition of associated block targets. a-c PTIMs informed by Roche Orphan Kinase Library and V3 screens. Targets of sunitinib are highlighted red, targets of BEZ235 are highlighted blue. a Abbreviated PTIM for PCB490–3. b Abbreviated PTIM for PCB490–4. c Abbreviated PTIM from PCB490–5 with integrated RNA-seq data. d Results from PCB490–5 patient-derived xenograft in vivo validation studies presented as group-wide tumor volumes following vehicle treatment (n = 3 mice, green line), treatment by 30.0 mg/kg sunitinib (n = 3 mice, red line), treatment by 25.0 mg/kg BEZ235 (n = 3 mice, blue line), and treatment by 25.0 mg/kg BEZ235 + 30.0 mg/kg sunitinib (n = 3 mice, purple line)

Back to article page